Graduate Studies Faculty
Sergio Fazio, M.D., Ph.D.
Programs:Physiology & Pharmacology
Program in Molecular & Cellular Biosciences
Research Interests:Lipoproteins, Atherosclerosis, Macrophages, Ischemic Disease, Mouse Models, Clinical studies, Cholesterol, Vascular Biology, Inflammation, Population Studies, Developmental Origins of Disease, Therapeutics Development, Cell Biology, PCSK9, LRP-1, ApoE, ApoAI, LDLR, ABCA1, SR-BI, ACAT, LCAT, CETP, CESD, ApoB, Oxidized Lipoproteins, Diagnostic Assay Development.
Preceptor RotationsDr. Fazio has not indicated availability for preceptor rotations at this time.
Faculty MentorshipDr. Fazio has not indicated availability as a mentor at this time.
A graduate of the medical school of the University of Rome, Italy, Dr. Fazio continued at the same institution with a fellowship in Metabolic Diseases. In 1985, he undertook a Ph.D. program in Experimental Medicine at the University of Siena, Italy, and completed it at the University of California, San Francisco (UCSF). In 1988 Dr. Fazio joined the Gladstone Institute of Cardiovascular Disease, UCSF, as a postdoctoral scientist first, and then as a Staff Scientist (Instructor in Medicine, UCSF).
In 1993 Dr. Fazio joined the faculty of the School of Medicine at Vanderbilt University as an Assistant Professor in the Division of Endocrinology and Diabetes. There, he co-founded the Vanderbilt Lipid Clinic and became Director of the Vanderbilt Lipid Laboratory. He was promoted to the rank of Associate Professor in July 1998. In November of 1999 Dr. Fazio joined the Division of Cardiovascular Medicine to become the co-Director of the Atherosclerosis Research Unit. He was promoted to Professor in November 2002. In 2011 he was appointed the Cornelius Vanderbilt Chair of Cardiovascular Medicine and Chief of the section of Cardiovascular Disease Prevention. Since July 2014 he holds the William and Sonja Connor chair of Preventive Cardiology at the KCVI of OHSU.
His clinical interest is the management of dyslipidemic patients. He participates in clinical trials to study the effectiveness and efficacy of lipid-lowering drugs, and is involved in the determination of new mutations causing altered lipid levels in humans. Dr. Fazio’s NIH-supported research portfolio focuses on the pathogenesis of genetic dyslipidemias, the early cellular events in atherogenesis, and gene therapy approaches to atherosclerosis. He has been an Established Investigator of the American Heart Association and is PI and Co-PI on several NIH grants. He has published over 180 papers, including original articles, reviews, editorials, and book chapters. He has been a charter member of the Study Section Atherosclerosis and Inflammation in Cardiovascular Disease of the NIH-NHLBI from 2006 to 2010. He is member of the American Society for Clinical Investigation and of the Association of American Physicians. He is on the editorial board of Arteriosclerosis, Thrombosis and Vascular Biology and of Circulation Research, and is an associate editor for theJournal of Clinical Lipidology.